Control of Propionibacterium acnes by natural antimicrobial substances: Role of the bacteriocin AS-48 and lysozyme
Metadata
Show full item recordAuthor
Cebrián Castillo, Rubén; Arévalo, Sergio; Rubiño, Susana; Arias Santiago, Salvador Antonio; Rojo, María Dolores; Montalbán-López, Manuel; Martínez Bueno, Manuel; Valdivia Martínez, Dolores Eva; Maqueda Abreu, MercedesEditorial
Springer Nature
Date
2018-08-06Referencia bibliográfica
Cebrián, R., Arévalo, S., Rubiño, S., Arias-Santiago, S., Rojo, M. D., Montalbán-López, M., ... & Maqueda, M. (2018). Control of Propionibacterium acnes by natural antimicrobial substances: role of the bacteriocin AS-48 and lysozyme. Scientific reports, 8(1), 11766.
Sponsorship
This research was funded by a grant from the Spanish Ministry of Economy and Competitiveness (SAF2013-48971-C2-1-R that included funds from European Regional Development, ERDF), and the Research Group General (BIO160, UGR).Abstract
We report the high susceptibility of several clinical isolates of Propionibacterium acnes from different
sources (skin, bone, wound exudates, abscess or blood contamination) to the head-to-tail cyclized
bacteriocin AS-48. This peptide is a feasible candidate for further pharmacological development against
this bacterium, due to its physicochemical and biological characteristics, even when it is growing in a
biofilm. Thus, the treatment of pre-formed biofilms with AS-48 resulted in a dose- and time-dependent
disruption of the biofilm architecture beside the decrease of bacterial viability. Furthermore, we
demonstrated the potential of lysozyme to bolster the inhibitory activity of AS-48 against P. acnes,
rendering high reductions in the MIC values, even in matrix-growing cultures, according to the results
obtained using a range of microscopy and bioassay techniques. The improvement of the activity of
AS-48 through its co-formulation with lysozyme may be considered an alternative in the control of P.
acnes, especially after proving the absence of cytotoxicity demonstrated by these natural compounds
on relevant human skin cell lines. In summary, this study supports that compositions comprising the
bacteriocin AS-48 plus lysozyme must be considered as promising candidates for topical applications
with medical and pharmaceutical purposes against dermatological diseases such as acne vulgaris.